ALX Oncology News

Express News | ALX Oncology Appoints Allison Dillon as Chief Business Officer

ReutersMay 7 09:00 ET

ALX Oncology Holdings (NASDAQ:ALXO) Has Debt But No Earnings; Should You Worry?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital.' So it seems

Simply Wall StMay 4 08:39 ET

ALX Oncology Board Reshuffles Following Director Resignations

TipRanksMay 2 16:26 ET

Express News | ALX Oncology Announces Initiation Of Phase 2 Investigator-Sponsored Trial Of Neoadjuvant RadiationAand Evorpacept In Combination With Pembrolizumab In Patients With Untreated HPV-Mediated Oropharyngeal Cancer

BenzingaApr 30 09:12 ET

Express News | ALX Oncology Announces Initiation of Phase 2 Investigator-Sponsored Trial of Neoadjuvant Radiation and Evorpacept in Combination With Pembrolizumab in Patients With Untreated Hpv-Mediated Oropharyngeal Cancer

ReutersApr 30 09:00 ET

ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual Meeting

SOUTH SAN FRANCISCO, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or "the Company") (NASDAQ:ALXO), an immuno-oncology company developing therapies that block the CD47 immune

GlobeNewswireApr 24 10:00 ET

ALX Oncology(ALXO.US) Officer Sells US$710.2K in Common Stock

$ALX Oncology(ALXO.US)$ Officer Pons Jaume sold 50,000 shares of common stock on Apr 16, 2024 at an average price of $14.2039 for a total value of $710.2K.Source: Announcement What is statement of cha

moomoo NewsApr 18 17:31 ET

Alx Oncology Holdings Insider Sold Shares Worth $710,195, According to a Recent SEC Filing

Jaume Pons, Director, President & Chief Scientific Officer, on April 16, 2024, sold 50,000 shares in Alx Oncology Holdings (ALXO) for $710,195. Following the Form 4 filing with the SEC, Pons has contr

MT NewswiresApr 18 16:52 ET

Why Travelers Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Shares of The Travelers Companies, Inc. (NYSE:TRV) fell sharply during Wednesday's session following first-quarter earnings. Travelers reported a mixed first quarter, with earnings lagging analyst' e

BenzingaApr 17 13:36 ET

United Airlines Reports Upbeat Results, Joins Children's Place, Interactive Brokers And Other Big Stocks Moving Higher On Wednesday

U.S. stocks were lower, with the Dow Jones index falling over 50 points on Wednesday. Shares of United Airlines Holdings, Inc. (NASDAQ:UAL) rose sharply during Wednesday's session after the company r

BenzingaApr 17 10:55 ET

ENPH, OCUL and ITCI Are Among After Hour Movers

Seeking AlphaApr 16 17:02 ET

Express News | Cantor Fitzgerald Reiterates Overweight on ALX Oncology Holdings

Moomoo 24/7Apr 12 09:42 ET

Express News | HC Wainwright & Co. Reiterates Buy on ALX Oncology Holdings, Maintains $20 Price Target

Moomoo 24/7Apr 10 11:18 ET

Buy Rating on ALX Oncology Holdings Amid Strong Clinical Data and Favorable RNPV Analysis

TipRanksApr 10 11:15 ET

ALX Oncology Reports Positive Data From Ongoing Phase 1/2 Trial of Evorpacept

ALX Oncology Holdings (ALXO) said Tuesday that data from the ongoing phase 1/2 trial of evorpacept, in combination with standard rituximab and lenalidomide, in patients with indolent and aggressive re

MT NewswiresApr 10 05:13 ET

ALX Oncology Reports Clinical Data From Ongoing Phase 1/2 Investigator-Sponsored Trial Of Evorpacept In Combination With R2 In Patients With Indolent And Aggressive R/R B-NHL

The new data were presented in an oral presentation at the 2024 American Association for Cancer Research Annual Meeting. Patients received evorpacept 30 mg/kg Q2W (n=3) or 60 mg/kg Q4W (n=17) in combi

BenzingaApr 9 17:35 ET

ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination With Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma ("R/R B-NHL")

ALX Oncology Holdings (Nasdaq: ALXO) today reported encouraging clinical data from the ongoing Phase 1/2 investigator-sponsored trial ("IST") of evorpacept in combination with R2 in patients with indolent and aggressive R/R B-NHL.

GlobeNewswireApr 9 17:30 ET

Analysts' Top Healthcare Picks: Alnylam Pharma (ALNY), ALX Oncology Holdings (ALXO)

TipRanksApr 8 06:40 ET

ALX Oncology Holdings Inc (ALXO) Insider Sells Shares

Yahoo FinanceApr 6 01:33 ET

ALX Oncology(ALXO.US) Officer Sells US$223.04K in Common Stock

$ALX Oncology(ALXO.US)$ Officer Pons Jaume sold 20,000 shares of Common Stock on Apr 4, 2024 at an average price of $11.1518 for a total value of $223.04K.Source: Announcement What is statement of cha

moomoo NewsApr 5 18:18 ET